Search research articles
Contact Us
Filters
Showing results (111-120 of 181) with videos related to
Page
of 19
Sort By:
Antiviral Therapy
|
July 19, 2012
Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function
Arkaitz Imaz, Montserrat Olmo, Maria Peñaranda, et al.
Atherosclerosis
|
September 29, 2012
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy
Maria Saumoy, José Luis Sánchez-Quesada, Esteban Martínez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 1, 2008
Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study
Vicenç Falcó, Montserrat Olmo, Sara Villar del Saz, et al.
Viruses
|
June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 12, 2015
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
Sharon Walmsley, Axel Baumgarten, Juan Berenguer, et al.
The Lancet. HIV
|
June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Jean-Michel Molina, Douglas Ward, Indira Brar, et al.
Antiviral Therapy
|
February 4, 2012
Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy
Arkaitz Imaz, Montserrat Olmo, Maria Peñaranda, et al.
AIDS Research and Human Retroviruses
|
July 14, 2010
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial
José M Miró, Christian Manzardo, Judith Pich, et al.
Current HIV Research
|
November 26, 2009
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain
Beatriz Mothe, Iñaki Perez, Pere Domingo, et al.
AIDS (London, England)
|
June 22, 2022
Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV
Laura Donadeu, Juan Manuel Tiraboschi, Sofía Scévola, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 181) with videos related to
Sort By:
Page
of 19
Antiviral Therapy
|
July 19, 2012
Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function
Arkaitz Imaz, Montserrat Olmo, Maria Peñaranda, et al.
Atherosclerosis
|
September 29, 2012
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy
Maria Saumoy, José Luis Sánchez-Quesada, Esteban Martínez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 1, 2008
Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study
Vicenç Falcó, Montserrat Olmo, Sara Villar del Saz, et al.
Viruses
|
June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 12, 2015
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
Sharon Walmsley, Axel Baumgarten, Juan Berenguer, et al.
The Lancet. HIV
|
June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Jean-Michel Molina, Douglas Ward, Indira Brar, et al.
Antiviral Therapy
|
February 4, 2012
Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy
Arkaitz Imaz, Montserrat Olmo, Maria Peñaranda, et al.
AIDS Research and Human Retroviruses
|
July 14, 2010
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial
José M Miró, Christian Manzardo, Judith Pich, et al.
Current HIV Research
|
November 26, 2009
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain
Beatriz Mothe, Iñaki Perez, Pere Domingo, et al.
AIDS (London, England)
|
June 22, 2022
Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV
Laura Donadeu, Juan Manuel Tiraboschi, Sofía Scévola, et al.
Page
of 19